Table S5.
Alternative scenario results: other comparisons
| Scenario | OnabotulinumtoxinA
|
BSC
|
Incremental (onabotulinumtoxinA vs BSC)
|
||||
|---|---|---|---|---|---|---|---|
| Total costs (discounted) | QALYs | Total costs (discounted) | QALYs | Total costs (discounted) | QALYs | ICERs | |
| Base case | £20,573 | 11.964 | £9,357 | 11.735 | £11,216 | 0.229 | £48,978 |
| Considering 10 weeks reinjection interval for onabotulinumtoxinA* | £21,968 | 11.954 | £9,277 | 11.693 | £12,691 | 0.261 | £48,625 |
|
| |||||||
| Scenario |
IncobotulinumtoxinA
|
BSC
|
Incremental (IncobotulinumtoxinA vs BSC)
|
||||
| Total costs (discounted) | QALYs | Total costs (discounted) | QALYs | Total costs (discounted) | QALYs | ICERs | |
|
| |||||||
| Base case | £22,473 | 11.959 | £9,357 | 11.735 | £13,116 | 0.224 | £58,554 |
| Considering 10 weeks reinjection interval for incobotulinumtoxinA* | £21,364 | 11.962 | £9,277 | 11.693 | £12,087 | 0.269 | £44,933 |
Note:
*
Same reinjection interval (10 weeks) was assumed for BSC.
Abbreviations: BSC, best supportive care; ICERs, incremental cost-effectiveness ratios; QALYs, quality-adjusted life-years.